Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year
- B D Gaynor1,
- K A Holbrook2,
- J P Whitcher1,
- S O Holm3,
- H C Jha4,
- J S P Chaudhary4,
- R C Bhatta4,
- T Lietman1
- 1The Francis I Proctor Foundation and the Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA
- 2Community Health Epidemiology and Disease Control, San Francisco Department of Public Health, San Francisco, CA, USA
- 3The Francis I Proctor Foundation
- 4Geta Eye Hospital, Geta, Nepal
- Correspondence to: Bruce D Gaynor, MD, The Francis I Proctor Foundation and the Department of Ophthalmology, UCSF Medical Center, San Francisco, CA 94143–0944, USA;
- Accepted 19 March 2002
Aims: To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma.
Methods: A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year after administering a single dose of azithromycin to treat trachoma in a village in Nepal.
Results:S pneumoniae was isolated from 50 (86%) of 57 nasopharyngeal cultures and no resistance to azithromycin was detected.
Conclusion: The authors were unable to demonstrate that mass azithromycin therapy for trachoma produced macrolide resistant S pneumoniae that persists until the next scheduled annual treatment.